Novo Nordisk A/S vs Wells Fargo & Co — how do they compare? Novo Nordisk A/S trades at $45.93 (market cap $207.85B), while Wells Fargo & Co trades at $87.48 (market cap $264.66B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | WFC | |
|---|---|---|
Market Cap | $207.85B | $264.66B |
Sector | Health | Financials |
52-Week High | $63.98 | $96.40 |
52-Week Low | $35.29 | $73.42 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 2.29% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →